Cardiol Therapeutics/$CRDL
1D1W1MYTD1Y5YMAX
About Cardiol Therapeutics
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
- Ticker
- $CRDL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 18
- Headquarters
- Oakville, Canada
- Website
- www.cardiolrx.com
CRDL Metrics
BasicAdvanced
$227M
-
-$0.24
0.47
-
Price and volume
Market cap
$227M
Beta
0.47
52-week high
$2.28
52-week low
$0.88
Average daily volume
1.3M
Financial strength
Current ratio
5.553
Quick ratio
5.015
Long term debt to equity
0.273
Total debt to equity
0.445
Profitability
EBITDA (TTM)
-25.781
Management effectiveness
Return on assets (TTM)
-90.92%
Return on equity (TTM)
-190.18%
Valuation
Price to book
13.02
Price to tangible book (TTM)
13.02
Price to free cash flow (TTM)
-11.377
Free cash flow yield (TTM)
-8.79%
Free cash flow per share (TTM)
-0.171
Growth
Earnings per share change (TTM)
-29.58%
3-year earnings per share growth (CAGR)
-10.81%
What the Analysts think about CRDL
Analyst ratings (Buy, Hold, Sell) for Cardiol Therapeutics stock.
CRDL Financial Performance
Revenues and expenses
CRDL Earnings Performance
Company profitability
CRDL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.